- Home
- TOMZ vs NRSN Comparison
TOMZ vs NRSN Comparison
Compare TOMZ & NRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TOMZ | NRSN |
|---|---|---|
| Founded | 1979 | 2017 |
| Country | United States | Israel |
| Employees | 20 | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.2M | 14.2M |
| IPO Year | 2009 | 2021 |
Fundamental Metrics
Financial Performance| Metric | TOMZ | NRSN |
|---|---|---|
| Price | $1.57 | $7.24 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 11.9K | ★ 515.9K |
| Earning Date | 05-12-2026 | 03-31-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 13.64 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $5,635,927.00 | N/A |
| Revenue This Year | $48.56 | N/A |
| Revenue Next Year | $121.37 | $583.67 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.50 | $0.25 |
| 52 Week High | $2.12 | $1.30 |
Technical Indicators
Market Signals| Indicator | TOMZ | NRSN |
|---|---|---|
| Relative Strength Index (RSI) | 42.93 | 91.51 |
| Support Level | $0.68 | $0.66 |
| Resistance Level | $1.95 | N/A |
| Average True Range (ATR) | 0.10 | 0.23 |
| MACD | -0.03 | 0.63 |
| Stochastic Oscillator | 10.00 | 87.17 |
Price Performance
Historical ComparisonAbout TOMZ TOMI Environmental Solutions Inc.
TOMI Environmental Solutions Inc is a leader in bacteria decontamination and infectious disease control, offering environmentally friendly solutions for indoor air and surface disinfection and decontamination. Its flagship product, SteraMist, uses patented and registered Binary Ionization Technology (BIT) to deliver a low-percentage hydrogen peroxide-based fog or mist to affect all indoor environments and surface areas. The product portfolio of the company includes The SteraPak, The Surface Unit, SteraMist Transport, The NV+, The Environment System, and others.
About NRSN NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.